SCHEMBL10186282

SCHEMBL10186282

Cc1ncnc2c1ccn2[C@@H]1C[C@@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 3/20 0.47
PRMT5 O14744 18/20 0.45
WDR77 Q9BQA1 6/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10186285 0.82 PRMT5 (0.35) PRMT5WDR77
SCHEMBL10186262 0.81 AHCY (0.52) METTL3PRMT5WDR77
SCHEMBL13170761 0.81 AHCY (0.54) METTL3PRMT5WDR77
SCHEMBL10186267 0.80 METTL3 (0.49) METTL3PRMT5WDR77
SCHEMBL192350 0.78 NAE1 (0.55) PRMT5WDR77
SCHEMBL10005101 0.78 NAE1 (0.55) PRMT5WDR77
SCHEMBL10186279 0.77 PRMT5 (0.38) PRMT5WDR77
SCHEMBL10186227 0.77 PRMT5 (0.37) PRMT5WDR77
SCHEMBL19667333 0.77 PRMT5 (0.52) PRMT5WDR77
SCHEMBL30207848 0.77 PRMT5 (0.52) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207177-B2 Inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-26 US disclosed
US-20070191293-A1 Inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191293-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 METTL3 4649/4885PRMT5 870/4885WDR77 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.